Yellow fever 17D vaccine safety and immunogenicity in the elderly.

  title={Yellow fever 17D vaccine safety and immunogenicity in the elderly.},
  author={Thomas P Monath and Martin S. Cetron and Karen Nora McCarthy and Richard S. Nichols and W Tad Archambault and Leisa Weld and Philip Bedford},
  journal={Human vaccines},
  volume={1 5},
The incidence of serious and severe multisystem adverse events (AEs) following yellow fever (YF) 17D vaccine is higher in persons of advanced age. One hypothesis for the occurrence of these AEs in the elderly is immunological senescence and a reduced ability to clear the vaccine virus infection. We determined age-specific rates of serious and nonserious AEs in two large clinical trials of two YF 17D vaccines from different manufacturers. In addition, we analyzed AEs reported in a large general… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 30 extracted citations

Yellow fever outbreak in Brazil, 2017.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases • 2017

Similar Papers

Loading similar papers…